Allogene (NASDAQ: ALLO) exec plans sale of 29,697 shares
Allogene Therapeutics, Inc. officer Douglas Earl Martin has filed a notice under Rule 144 to sell up to 29,697 shares of common stock, valued at $62,957.64, through Morgan Stanley Smith Barney LLC on or after August 21, 2026. These shares are part of a restricted stock unit award, with 81,719 shares vesting on August 20, 2026, as part of the company's equity compensation plan. The filing indicates a neutral impact and sentiment for the company.
Allogene Therapeutics, Inc. SEC Filing (Aug 21, 2026)
This article reports on an SEC filing by Allogene Therapeutics, Inc. (ALLO) dated August 21, 2026. The filing, a Form S-3, became effective on August 20, 2026, at 4:00 P.M. The article also provides a brief overview of the company's recent news and SEC filings, highlighting its market performance and a recent FDA RMAT designation.
Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
This article analyzes Allogene Therapeutics (NASDAQ:ALLO) and suggests it is in a strong financial position to invest in growth. It likely reviews the company's financial health, market performance, or strategic advantages that enable such investments. The analysis indicates a positive outlook regarding the company's capacity for future development.
Citizens reiterates Allogene stock rating on trial progress
Citizens reiterated a Market Outperform rating on Allogene Therapeutics Inc. (NASDAQ:ALLO), maintaining a $6.00 price target. The firm's analysis is based on discounted EPS and revenue multiples, with the company's ALPHA3 trial on track for an interim readout in mid-2027. Allogene reported strong second-quarter 2026 earnings, surpassing analyst expectations with a narrower loss and higher revenue.
Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO
Walleye Capital LLC has invested $6.80 million in Allogene Therapeutics, acquiring 3.27 million shares, representing approximately 0.95% of the company. Other institutional investors have also adjusted their stakes, with a significant 83.63% of the stock owned by institutional investors and hedge funds. Allogene Therapeutics recently reported a smaller-than-expected quarterly loss and maintains a "Moderate Buy" consensus rating from analysts, despite a recent downgrade from Weiss Ratings.
Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes
Frazier Life Sciences Public Fund, L.P. has reported a 5.6% ownership stake in Allogene Therapeutics (ALLO), holding 19,445,046 shares. Other affiliated Frazier funds also hold additional stakes, bringing the total reported beneficial ownership by various Frazier entities and individuals to a significant portion of Allogene's common stock. This disclosure is made via an amended Schedule 13G filing, detailing shared voting and dispositive powers for these holdings.
Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy
The FDA has granted RMAT and Fast Track designations to Allogene's TALEN-edited, allogeneic CD19 CAR T-cell therapy, cema-cel, for first-line consolidation in large B-cell lymphoma. An interim analysis showed cema-cel cleared minimal residual disease in a significant proportion of patients, with no serious adverse events reported. These designations aim to facilitate regulatory interaction for this innovative cell therapy.
Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary
Allogene Therapeutics is strategically shifting its CAR-T platform to focus on off-the-shelf availability and community treatment, particularly for high-risk patients. The company is accelerating site activation for its ALPHA3 program and is on track for key clinical updates and regulatory milestones for Cema-Cel and ALLO-329, despite acknowledging safety challenges in the TRAVERSE trial. Management anticipates minimal competitive impact due to the logistical advantages of their five-minute infusion profile over existing high-toxicity therapies.
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Allogene Therapeutics (ALLO) reported a narrower-than-expected Q2 2026 loss of 13 cents per share, beating the Zacks Consensus Estimate of 16 cents, primarily due to lower research and development costs. The company's cash position extended its runway into 2029, and it is progressing with its lead pipeline drug cema-cel in the ALPHA3 study and ALLO-329 for autoimmune diseases, with data updates expected later in 2026 and 2027.
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says
RBC Capital Markets reiterated that Allogene Therapeutics remains an attractive investment due to its appealing valuation and distinctive clinical strategy. The company highlighted a 41% improvement in minimal residual disease on the large B-cell lymphoma front. Access to the full analysis requires a premium subscription.
Allogene Therapeutics, Inc. Announces Cemacabtagene Ansegedleucel (Cema-Cel) Is Being Evaluated in Alpha3, the First Pivotal, Randomized Phase 2 Trial in LBCL
Allogene Therapeutics announced that cemacabtagene ansegedleucel (cema-cel) is being evaluated in ALPHA3, a pivotal Phase 2 trial for high-risk Large B-Cell Lymphoma (LBCL) patients. The trial aims to assess if MRD-guided treatment can delay or prevent relapse, with early data showing favorable MRD negativity rates and a well-tolerated safety profile for cema-cel. The company also provided an update on its ALLO-329 program for autoimmune diseases, which continues enrollment in its Phase 1 RESOLUTION trial.
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
Allogene Therapeutics (ALLO) reported a narrower-than-expected loss of 13 cents per share in Q2 2026, surpassing the Zacks Consensus Estimate of 16 cents, primarily due to reduced research and development costs. The company's cash position extended its runway into 2029, and it is making significant progress in its ALPHA3 study for cema-cel and its RESOLUTION study for ALLO-329 in autoimmune diseases.
722,928 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Hennion & Walsh Asset Management Inc.
Hennion & Walsh Asset Management Inc. has acquired a new position of 722,928 shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO), valued at approximately $1.5 million. This purchase gives the firm a 0.21% stake in the company, contributing to the 83.63% institutional ownership of Allogene. The acquisition comes as Allogene's cema-cel program received FDA RMAT and Fast Track designations, and the company reported a smaller-than-expected second-quarter loss of $0.13 per share.
Earnings call transcript: Allogene Therapeutics beats Q2 2026 EPS forecast
Allogene Therapeutics reported a narrower-than-expected loss for Q2 2026, with adjusted EPS of negative $0.13 against a forecast of negative $0.17. Revenue significantly surpassed expectations, driven primarily by clinical advancements rather than financial metrics. The company's ALPHA3 trial in large B-cell lymphoma is progressing well, with regulatory designations strengthening its position, and the stock saw an after-hours increase following the mixed market reaction during regular trading.
Allogene Therapeutics earnings beat by $0.04, revenue topped estimates
Allogene Therapeutics (NASDAQ: ALLO) reported better-than-expected earnings for the second quarter, beating analyst EPS estimates by $0.04 and significantly exceeding revenue forecasts. The company posted an EPS of $-0.130 on revenue of $4.64M. The stock has shown strong performance, rising 2.750% in the last three months and 97.600% over the past year.
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported its second-quarter 2026 financial results, highlighting significant progress in its clinical trials for cancer and autoimmune diseases. The company's cema-cel program received RMAT and Fast Track designations from the FDA, and its ALPHA3 trial is accelerating site activations ahead of schedule. Allogene ended the quarter with $423.6 million in cash, projecting a runway into 2029.
Allogene Therapeutics: Q2 Earnings Snapshot
Allogene Therapeutics Inc. reported a Q2 loss of $42.7 million, or 13 cents per share, surpassing Wall Street expectations which had forecast a loss of 16 cents per share. The immuno-oncology company generated $4.5 million in revenue for the period. Shares of Allogene Therapeutics were trading at $2.08 on Wednesday, double their value from a year ago.
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported its second-quarter 2026 financial results, highlighting significant progress in its ALPHA3 program for cema-cel in 1L Large B-cell Lymphoma, which received RMAT and Fast Track designations from the FDA. The company also provided an update on its Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease, with clinical data expected in Q4 2026. Allogene ended the quarter with $423.6 million in cash, projecting a cash runway into 2029.
Allogene Therapeutics, Inc. expected to post a loss of 17 cents a share - Earnings Preview
Allogene Therapeutics, Inc. is projected to report a loss of 17 cents per share. This information comes from an earnings preview, indicating an anticipated financial performance for the company. The full article provides more details, accessible through a TradingView subscription.
State Street Corporation (ALLO) discloses 5.5% beneficial stake in Allogene
State Street Corporation has disclosed a 5.5% beneficial ownership stake in Allogene Therapeutics, Inc., holding 19,025,826 shares of common stock. The filing, a Schedule 13G, indicates that State Street exercises shared voting power over 18,772,433 shares and shared dispositive power over all 19,025,826 shares, with no sole voting or dispositive power. Several State Street subsidiaries, including SSGA Funds Management, Inc., are involved in these holdings.
Allogene Therapeutics (ALLO) stake: Belldegrun group reports 3.9% ownership
Dr. Arie Belldegrun and affiliated entities have filed an amended passive ownership report for Allogene Therapeutics (ALLO), disclosing a beneficial ownership of 13,610,578 shares, which represents 3.9% of the outstanding common stock as of May 11, 2026. This total includes shares from stock options and holdings through Bellco Legacy and Vida Ventures. The filing confirms that each reporting person now owns 5% or less of Allogene's outstanding common stock.
Allogene Therapeutics Q2 Results: Earnings Call Set for Aug 12
Allogene Therapeutics will report its Q2 2026 financial results and provide a business update on August 12, 2026, after market close, followed by a webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The company, a clinical-stage biotechnology firm, focuses on developing allogeneic CAR T products for cancer and autoimmune diseases, aiming to make cell therapy more accessible. Investors can register for the call to participate or access a listen-only webcast and its replay on the company's website.
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Allogene Therapeutics announced it will report its second quarter 2026 financial results and provide a business update on August 12, 2026, after market close. This will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The company, a clinical-stage biotechnology firm, specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.
Allogene sets Aug. 12 update on cancer and autoimmune disease
Allogene Therapeutics (NASDAQ: ALLO) announced it will report its second-quarter 2026 financial results and provide a business update on August 12, 2026, after the market close. The company will host a live audio webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET, accessible via its investor relations website. Allogene specializes in developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmune diseases.
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Allogene Therapeutics, Inc. will report its second quarter 2026 financial results and provide a business update on August 12, 2026, after market close. A live audio webcast and conference call will follow at 2:00 p.m. PT/5:00 p.m. ET. The company, a clinical-stage biotechnology firm, specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.
Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations
Allogene Therapeutics announced that its drug, Cemacabtagene Ansegedleucel, received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration. This article from MT Newswires discusses the regulatory approvals for the company's treatment. However, the full details of the article require a premium subscription.
Insider Sellers Might Regret Selling Allogene Therapeutics Shares at a Lower Price Than Current Market Value
Insiders at Allogene Therapeutics, Inc. sold US$603k worth of stock over the past year at an average price of US$1.85, which is higher than the current share price of US$1.66. While a recent major sale by Co-Founder David Chang was near the current price, the overall trend suggests insiders might regret selling at lower prices. The company has modest insider ownership of 4.3% (US$26m), and no insider purchases have occurred in the last year, suggesting insiders might have missed out on potential gains.
Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk
Allogene Therapeutics Inc (ALLO) has a current risk assessment score of 3.70, placing it 115th out of 384 companies in the Biotechnology & Medical Research industry. The company's beta value of 0.47 indicates lower volatility compared to the S&P 500. The report details various risk metrics including VaR, maximum drawdown, volatility, and Sharpe Ratios over different timeframes.
Allogene Therapeutics stock rises on FDA regulatory designations
Allogene Therapeutics Inc. (NASDAQ:ALLO) shares increased after the FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to its experimental therapy cema-cel. These designations are for treating adult patients with large B-cell lymphoma (LBCL) who test positive for minimal residual disease (MRD) after first-line therapy. The regulatory statuses enable more frequent FDA engagement for an efficient development and review process, based on positive interim analysis data from the ALPHA3 trial.
Allogene Therapeutics, Inc. Receives FDA Regenerative Medicine Advanced Therapy And Fast Track Designations For Cemacabtagene Ansegedleucel As First-Line Consolidation Therapy For Large B-Cell Lymphoma
Allogene Therapeutics has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for its investigational CAR T product, cemacabtagene ansegedleucel (cema-cel). These designations are for cema-cel as a first-line consolidation therapy for adult patients with high-risk large B-cell lymphoma (LBCL) who show positive results for minimal residual disease (MRD) after initial therapy. The decision was based on promising interim analysis from the ALPHA3 trial, which demonstrated a significant increase in MRD negativity in the cema-cel arm compared to the observation arm, with a favorable safety profile.
Allogene Reports No Minimal Residual Disease in 7 of 12 Cema-Cel Patients
Allogene Therapeutics announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to its investigational allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel). These designations are based on interim data from the pivotal ALPHA3 trial, where 58.3% of cema-cel-treated patients achieved MRD negativity by Day 45, significantly outperforming the observation arm. The therapy also demonstrated a favorable safety profile, and these regulatory recognitions are expected to expedite its development and review process for adult large B-cell lymphoma patients who are MRD-positive after initial chemoimmunotherapy.
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Allogene Therapeutics has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for its investigational allogeneic CAR T product, cemacabtagene ansegedleucel (cema-cel). These designations are for cema-cel's use as a first-line consolidation therapy for adult patients with high-risk large B-cell lymphoma (LBCL) who test positive for minimal residual disease (MRD) after initial treatment. The decision is based on promising interim futility analysis from the ALPHA3 trial, which showed rapid and substantial MRD reduction and good tolerability, highlighting cema-cel's potential to transform LBCL treatment.
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Allogene Therapeutics announced that the FDA has granted both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its investigational allogeneic CAR T product, cemacabtagene ansegedleucel (cema-cel). These designations are for cema-cel as a first-line consolidation therapy for adult patients with high-risk large B-cell lymphoma (LBCL) who are MRD-positive after initial treatment. The decision is based on strong interim data from the ALPHA3 trial, showing rapid and substantial MRD clearance with a favorable safety profile, enabling mostly outpatient treatment.
Insider Sellers Might Regret Selling Allogene Therapeutics Shares at a Lower Price Than Current Market Value
Insiders at Allogene Therapeutics sold US$603k worth of shares over the past year at an average price of US$1.85, which is lower than the current share price. This suggests that these sellers might now regret their decision given the stock's recent price movements, despite a 10% fall in the last week. While insider selling occurred, the sales were around the current price, and insiders still own 4.3% of the company's shares.
Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations
Allogene Therapeutics announced that its drug candidate, Cemacabtagene Ansegedleucel (cema-cel), has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA. These designations are for cema-cel as a first-line consolidation therapy for large B-cell lymphoma. The company's stock, trading on Nasdaq, reflects these developments.
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Allogene Therapeutics announced that its investigational allogeneic CAR T product, cemacabtagene ansegedleucel (cema-cel), has received both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA. These designations are for its use as a first-line consolidation therapy for adult patients with high-risk large B-cell lymphoma (LBCL). The decision follows positive interim futility analysis data from the ALPHA3 trial, showing rapid and substantial minimal residual disease (MRD) clearance and a favorable safety profile for cema-cel.
Allogene Therapeutics Inc (ALLO) Financial Health: Profitability & Balance Sheet Analysis
The article provides an analysis of Allogene Therapeutics Inc (ALLO)'s financial health, noting its current financial score of 5.10 and a ranking of 377 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. Key financial metrics such as cash and cash equivalents, total assets, total liabilities, and free cash flow were not disclosed by the company, impacting the assessment of its quality of earnings, operational efficiency, growth potential, and shareholder returns.
Allogene Therapeutics, Inc. Stock 12‑Month Price Target Cut to $8.75, Implies 381% Upside
Allogene Therapeutics, Inc.'s average 12-month stock price target has been lowered to $8.75 from $9 by 8 analysts, with forecasts ranging from $4 to $14 per share. This new target suggests a potential upside of approximately 381% based on the July 23 closing price. The consensus rating for ALLO remains "Buy" from 11 analysts.
Allogene Therapeutics Inc (ALLO) Cash Flow
This article provides a detailed cash flow statement for Allogene Therapeutics Inc (ALLO) on a quarterly and annual basis. It breaks down operating, investing, and financing cash flows, including specific line items such as net income from continuing operations, capital expenditures, and changes in working capital. The data spans from FY2018Q1 to FY2026Q1, offering a comprehensive look at the company's financial movements.
Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Allogene Therapeutics Inc (ALLO)'s dividend history and stock splits. It states that the company has distributed $0.00 in dividends over the past five years and currently has no dividend data available. The content primarily focuses on the company's financial overview, stock price, and market capitalization, along with sections for discussions and analysis.
Allogene Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLO
The article provides a revenue breakdown for Allogene Therapeutics, Inc. (NASDAQ: ALLO) as listed on TradingView. It indicates that the market is currently closed with no trades. The content primarily outlines the financial overview, statements, statistics, dividends, earnings, and market data sources for the company.
Allogene’s ALLO-316 Achieves 31% Response Rate in Advanced Renal Cell Carcinoma
Allogene's investigational CAR T candidate, ALLO-316, demonstrated a 31% confirmed response rate in Stage IV renal cell carcinoma patients with high CD70 tumor proportion scores, who had previously failed immune checkpoint blockade and at least one TKI. The Phase 1 TRAVERSE data, published in the Journal of Clinical Oncology, highlighted durable responses exceeding 18 months, with no grade 3 or higher cytokine release syndrome in Phase 1b and no observed graft-versus-host disease. These results suggest a promising new therapeutic approach for heavily pretreated RCC patients.
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Allogene Therapeutics announced the publication of complete Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic CAR T therapy for advanced renal cell carcinoma, in the Journal of Clinical Oncology. The study showed ALLO-316 achieved a 31% confirmed response rate with the recommended Phase 2 regimen in patients with high CD70 expression, demonstrating durable responses and a manageable safety profile. These results validate the company's Dagger® technology and support the continued clinical development of ALLO-316 for metastatic solid tumors.
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Allogene Therapeutics announced the publication of complete Phase 1 data for its investigational therapy ALLO-316 in the Journal of Clinical Oncology, showing durable remissions in metastatic solid tumors. The TRAVERSE study, conducted in collaboration with The University of Texas MD Anderson Cancer Center, focused on advanced or metastatic renal cell carcinoma. ALLO-316 achieved a 31% confirmed response rate with the recommended Phase 2 regimen in patients with high CD70 expression, demonstrating robust expansion and tumor infiltration while maintaining a manageable safety profile.
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Allogene Therapeutics announced the publication of complete Phase 1 data for ALLO-316 in the Journal of Clinical Oncology, showing durable remissions in metastatic solid tumors, specifically renal cell carcinoma (RCC). The study highlighted a 31% confirmed response rate with the recommended Phase 2 regimen in RCC patients with high CD70 expression, demonstrating robust expansion and tumor infiltration of ALLO-316. These results validate Allogene's Dagger® technology as a next-generation allogeneic CAR T platform and support further clinical development for advanced RCC.
Allogene Therapeutics (ALLO) Q3 2024 earnings summary
Allogene Therapeutics released its Q3 2024 earnings summary, highlighting the advancement of its key trials, including the pivotal Phase 2 ALPHA3 trial for cema-cel, with enrollment expected to complete in H1 2026. The company reported $403.4 million in cash, cash equivalents, and investments, providing a runway into the second half of 2026, despite a net loss of $66.3 million for the quarter. Allogene also expanded its CD19 license territory to include the EU and UK and is strategically reducing its workforce by 22% to prioritize core programs and extend its cash runway.
Allogene Therapeutics (ALLO) Proxy filing Summary
Allogene Therapeutics (ALLO) issued a proxy filing summary on May 21, 2026, correcting total compensation figures for Dr. Chang (2024), Dr. Roberts (2025), and Mr. Parker (2025) in their Summary Compensation Table, with no other changes to the proxy statement or proposals for the 2026 annual meeting. Shareholders are asked to approve, on a non-binding advisory basis, the compensation of named executive officers. The updated compensation table details various forms of compensation, including salary, bonus, RSU, PSU, option awards, non-equity incentives, and other benefits for 2024 and 2025.
Allogene Therapeutics (ALLO) Q3 2024 earnings summary
Allogene Therapeutics reported its Q3 2024 earnings, highlighting progress in its ALPHA3 trial for cema-cel, which aims to complete enrollment by H1 2026 and deliver primary data by year-end 2026. The company also received RMAT designation for ALLO-316 in renal cell carcinoma and expanded its pipeline with ALLO-329 for autoimmune diseases. Financially, Allogene had $403.4 million in cash, cash equivalents, and investments, with a runway into the second half of 2026, and reported a net loss of $66.3 million for Q3 2024.
Cancer cell therapy pioneer Allogene’s new CEO is talking about a new revolution
Zach Roberts, the new CEO of Allogene Therapeutics Inc., is advocating for a revolutionary approach to cancer cell therapy. He aims to champion new methods to address this deadly disease. The article describes Roberts' vision for the future of cancer treatment at Allogene.
Allogene Therapeutics (ALLO) CEO granted 476,190 options and 134,530 RSUs
Allogene Therapeutics President and CEO Zachary Roberts was granted 476,190 stock options with an exercise price of $2.11 per share and 134,530 Restricted Stock Units (RSUs). These equity awards are compensation-related and not open-market transactions. The stock options vest over time, with 25% on July 1, 2027, and the remainder in monthly installments, while the RSUs vest in four equal annual installments starting July 20, 2026, both subject to continued service.
